Literature DB >> 18766999

Beta emitters and radiation protection.

Lars Jødal1.   

Abstract

BACKGROUND: Beta emitters, such as (90)Y, are increasingly being used for cancer treatment. However, beta emitters demand other precautions than gamma emitters during preparation and administration, especially concerning shielding. AIM: To discuss practical precautions for handling beta emitters in general, and specifically determine proper shielding for (90)Y, while comparing to (177)Lu and (131)I. The aim is achieved through the application of physical principles combined with results from practical experience.
MATERIAL AND METHODS: Typical and maximal electron ranges were calculated for (131)I, (177)Lu, and (90)Y, using data from a freely available database. Bremsstrahlung yields were calculated for (90)Y shielded by lead, aluminium, or perspex. Bremsstrahlung spectrum from (90)Y shielded by perspex was measured, and attenuation of spectrum by lead was calculated. Whole-body and finger doses to persons preparing (90)Y-Zevalin were measured.
CONCLUSIONS: Good laboratory practice is important to keep radiation doses low. To reduce bremsstrahlung, (90)Y should not be shielded by lead but instead perspex (10 mm) or aluminium (5 mm). Bremsstrahlung radiation can be further reduced by adding a millimetre of lead on the outside of the primary shielding material. If suitable shielding is used and larger numbers of handlings are divided among several persons, then handling of beta emitters can be a safe procedure.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 18766999     DOI: 10.1080/02841860802245163

Source DB:  PubMed          Journal:  Acta Oncol        ISSN: 0284-186X            Impact factor:   4.089


  5 in total

1.  Radiation exposure, protection and risk from nuclear medicine procedures.

Authors:  Massimo Salvatori; Giovanni Lucignani
Journal:  Eur J Nucl Med Mol Imaging       Date:  2010-06       Impact factor: 9.236

2.  Transcriptional Response in Mouse Thyroid Tissue after 211At Administration: Effects of Absorbed Dose, Initial Dose-Rate and Time after Administration.

Authors:  Nils Rudqvist; Johan Spetz; Emil Schüler; Toshima Z Parris; Britta Langen; Khalil Helou; Eva Forssell-Aronsson
Journal:  PLoS One       Date:  2015-07-15       Impact factor: 3.240

3.  InfuShield: a shielded enclosure for administering therapeutic radioisotope treatments using standard syringe pumps.

Authors:  Dominic P Rushforth; Brenda E Pratt; Sarah J Chittenden; Iain S Murray; Louise Causer; Matthew J Grey; Jonathan I Gear; Yong Du; Glenn D Flux
Journal:  Nucl Med Commun       Date:  2017-03       Impact factor: 1.690

4.  Preclinical evaluation of a novel engineered recombinant human anti-CD44v6 antibody for potential use in radio-immunotherapy.

Authors:  Anja C Mortensen; Diana Spiegelberg; Anna-Karin Haylock; Hans Lundqvist; Marika Nestor
Journal:  Int J Oncol       Date:  2018-04-11       Impact factor: 5.650

5.  Long-term transcriptomic and proteomic effects in Sprague Dawley rat thyroid and plasma after internal low dose 131I exposure.

Authors:  Malin Larsson; Nils Rudqvist; Johan Spetz; Emman Shubbar; Toshima Z Parris; Britta Langen; Khalil Helou; Eva Forssell-Aronsson
Journal:  PLoS One       Date:  2020-12-31       Impact factor: 3.240

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.